Selinexor
As of the edition of 20 October 2026, Selinexor is a small molecule: marketed, first approved in 2019 (US); acts on XPO1; US protection ends in 2035.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2021
- Kind
- Small molecule
- Brand name
- Xpovio
- First approved
- 3 July 2019 (US)
- Approvals on record
- 7 in 2 regions
- Holder of the most recent approval
- Karyopharm Therapeutics; 2 holders in all
- Registered trials
- 187, 35 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Heart and blood vessels; Urinary and reproductive; Pregnancy and women's health
US protection
US protection ends in 2035.
The last listed US drug-substance patent ends in 2035. The application that gives this date is held by Karyopharm Therapeutics.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product47 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 47 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
2 companies on route B because of this drug.
Companies on route B for this drug
In the product2 companies are on route B because of Selinexor.
See the 2 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| XPO1 | Exportin-1 | O14980 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 13 | 1 | 7 | 0 |
| Phase 1 | 42 | 25 | 6 | 7 |
| Phase 2 | 116 | 20 | 56 | 28 |
| Phase 3 | 15 | 5 | 8 | 0 |
| Phase 4 | 1 | 0 | 0 | 0 |
| All trials | 187 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Karyopharm Therapeutics | Originator and Lead sponsor of trials | 2019 to now |
| Stemline Therapeutics | Applicant | 2021 to now |